Income from Continuous Operations (Annual)

Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.

Sino Biopharmaceutical (SBMFF) had Income from Continuous Operations of $665.53M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$4.02B
Net Income	$486.83M
Cost of Goods Sold	$742.27M
Gross Profit	$3.27B
Operating Expenses	$2.43B
Operating Income	$1.58B
Non-Operating Income/Expense	$-850.67M
Pre-Tax Income	$734.10M
Normalized Pre-Tax Income	$750.55M
Income after Taxes	$665.53M
Income from Continuous Operations	$665.53M
Consolidated Net Income/Loss	$885.33M
Normalized Income after Taxes	$683.52M
EBIT	$1.58B
EBITDA	$1.76B
Weighted-Average Shares Outstanding (Basic)	18.29B
Weighted-Average Shares Outstanding (Diluted)	18.30B
Earnings per Share (EPS) (Basic)	$0.03
Earnings per Share (EPS) (Diluted)	$0.03
Balance Sheet Financials
Current Assets	$3.43B
Property, Plant, and Equipment	$1.21B
Long-Term Assets	$5.66B
Total Assets	$9.10B
Current Liabilities	$2.72B
Long-Term Debt	$277.75M
Long-Term Liabilities	$428.08M
Total Liabilities	$3.15B
Common Equity	$5.95B
Tangible Shareholders Equity	$5.52B
Shareholders Equity	$5.95B
Common Shares Outstanding	18.79B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$920.16M
Cash Flow from Investing Activities	$-237.74M
Cash Flow from Financial Activities	$-878.43M
Beginning Cash	$1.04B
End Cash	$866.80M
Increase/Decrease in Cash	$-177.15M
Stock-Based Compensation	--
Common Stock Dividends Paid	$-308.09M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.26
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.04
Debt to Equity Ratio	0.22
Gross Margin	81.51%
Operating Margin	39.47%
EBIT Margin	39.47%
EBITDA Margin	43.75%
Pre-Tax Profit Margin	18.28%
Profit Margin	12.12%
Free Cash Flow	$796.47M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.44
Inventory Turnover	2.25
Receiveable Turnover	5.81
Days Sales in Receivables	62.81
Return on Equity	11.19%
Return on Tangible Equity	12.05%
Return on Assets	7.31%
Return on Investments	10.69%
Book Value Per Share	$0.32
Free Cash Flow per Share	$0.04
Operating Cash Flow per Share	$0.05

Data from Zacks Investment Research, Inc.